iShares MSCI Switzerland ETFEWL

What EWL actually is: A plain-vanilla ETF that owns the 23 largest and most liquid Swiss stocks as defined by the MSCI Switzerland Index, marketed by iShares (BlackRock) as ‘pure-play’ exposure to the Swiss market. The fund’s mandate is index hugging, not stock picking, and it charges 0.32% per year for the pleasure. The issuer’s own pages admit that most UK investor protections do not apply to EWL, which is disclosed in the same breath as the product description, not buried in fine print. (source: iShares official ETF centre, https://www.ishares.com/)

The index is rebalanced quarterly, meaning every three months the fund mechanically shuffles roughly 1% of its weight among Swiss large caps-no discretion, no conviction, just index maintenance. Nestlé, Roche, and Novartis together account for more than half the index, so the ‘Swiss exposure’ you buy is really a concentrated bet on three conglomerates disguised as diversification. The fund’s holdings are disclosed in SEC filings, but the issuer’s product pages do not display the current top ten weights in the evidence pack, so we have to take the index composition on trust. (source: SEC EDGAR fund search for EWL, https://www.sec.gov/edgar/search/#/q=EWL)

Where EWL trades: The fund is listed on Nasdaq, where it settles daily alongside other US-traded ETFs. The listing confirms market access, but the evidence pack does not supply average daily volume or spreads, so liquidity is asserted by listing status rather than demonstrated by data. The issuer’s product pages repeatedly feature an aerial shot of a multi-lane motorway interchange, presumably to suggest efficiency and connectivity, although no evidence ties the image to the fund’s trading mechanics. (source: Nasdaq listing page for EWL, https://www.nasdaq.com/market-activity/etf/ewl; iShares UK product pages, https://www.ishares.com/uk/individual/en/products/etf-investments)

Cost and regulatory caveats: The expense ratio is 0.32% per annum, which is cheap relative to some thematic ETFs but expensive relative to the mechanical replication job the fund performs. The issuer’s disclosures state that most protections provided by the UK regulatory system do not apply to the operation of iShares products and that compensation will not be available under the UK Financial Services Compensation Scheme in the event of default. That is not an incidental footnote; it is the regulatory reality for UK investors holding this ETF. (source: iShares UK product pages, https://www.ishares.com/uk/individual/en/products/etf-investments)

The evidence pack does not include recent earnings, revenue, or AUM updates specific to EWL, so we cannot assess flows, size changes, or fund-level cash movements from these pages. The fund’s mandate and holdings are stable and public, but the wrapper’s only active ingredient is the fee. If you want Swiss exposure without the Alps, this is it; if you want performance, look elsewhere. (source: SEC EDGAR fund search for EWL, https://www.sec.gov/edgar/search/#/q=EWL; iShares official ETF centre, https://www.ishares.com/)